News & Events May

CTI Partners with St. Elizabeth Healthcare and Pulmotect to Open First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19

May 18, 2020

FOR IMMEDIATE RELEASE [Covington, KY / Edgewood, KY ~ May 18, 2020] – St. Elizabeth Healthcare has been selected as the first site of the FDA-approved Phase-2 COVID-19 clinical trial studying the drug PUL-042 of Pulmotect, Inc., in partnership with CTI ...

Read More

CTI Partners with Pulmotect on Two Phase-2 Trials Targeting COVID-19

May 11, 2020

FOR IMMEDIATE RELEASE [Covington, KY ~ May 11, 2020] – CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, is partnering with Pulmotect, Inc., a clinical-stage biotechnology company, on two COVID-19 phase 2 clinical trials ...

Read More

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

May 7, 2020

First Phase III pivotal study for an anti-GM-CSF therapy in COVID-19 patients First patient dosed in US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product ...

Read More

Subscribe to our mailing list

* indicates required